Michael J. McElhaugh
Known title: Chief Business OfficerCIK: 0001635326
Associated companies
Transaction History
| ABUS | ▲ Buy | Grant | 177,000 | $0 | 2/14/2025 | View on chart |
| ABUS | ▼ Sell | Open Market | 23,790 | $78K | 2/4/2025 | View on chart |
| ABUS | ▼ Sell | Open Market | 10,164 | $24K | 2/2/2024 | View on chart |
| ABUS | ▲ Buy | Grant | 123,800 | $0 | 2/1/2024 | View on chart |
| ABUS | ▲ Buy | Grant | 83,700 | $0 | 2/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
ABUS Featured in Whale Alert List of 10 Health Care Stocks
Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.
ABUS Featured in Whale Alert List of 10 Health Care Stocks. Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.